Recent advancements of hydrogels in immunotherapy: Breast cancer treatment
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.06.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Jagannath Mondal und 6 weiteren Autor:innen. Beteiligte Einrichtung: 4D Convergence Technology Institute, Korea National University of Transportation, Jeungpyeong 27909, Republic of Korea; Department of Green Bioengine…. Hauptthemen laut MEDLINE: Hydrogels, Breast Neoplasms, Immunotherapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 252 Literaturangaben. Gefördert von: Ministry of Education, National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
Breast cancer is the most prevalent cancer among women and the leading cause of cancer-related deaths in this population. Recent advances in Immunotherapy, or combined immunotherapy, offering a more targeted and less toxic approach, expand the survival rate of patients more than conventional treatment. Notably, hydrogels, a versatile platform provided promising avenues to combat breast cancer in preclinical studies and extended to clinical practices. With advantages such as the alternation of tumor microenvironment, immunomodulation, targeted delivery of therapeutic agents, and their sustained release at specific sites of interest, hydrogels can potentially be used for the treatment of breast cancer. This review highlights the advantages, mechanisms of action, stimuli-responsiveness properties, and recent advancements of hydrogels for treating breast cancer immunotherapy. Moreover, post-treatment and its clinical translations are discussed in this review. The integration of hydrogels in immunotherapy strategies may pave the way for more effective, personalized, and patient-friendly approaches to combat breast cancer, ultimately contributing to a brighter future for breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 4D Convergence Technology Institute, Korea National University of Transportation, Jeungpyeong 27909, Republic of Korea; Department of Green Bioengineering, Korea National University of Transportation, Chungju 27470, Rep…
- Department of IT and Energy Convergence (BK21 FOUR), Korea National University of Transportation, Chungju 27469, Republic of Korea.
- Department of Green Bioengineering, Korea National University of Transportation, Chungju 27470, Republic of Korea.
- Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04763, Republic of Korea.
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, TX 79902, United States; Biomedical Engineering Program, College of Engineering, University of Texas at El Paso, El Pas…
Förderung
- Ministry of Education
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Mondal, J., Chakraborty, K., Bunggulawa, E. J., An, J. M., Revuri, V., Nurunnabi, M., & Lee, Y. K. (2024). Recent advancements of hydrogels in immunotherapy: Breast cancer treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.06.003
Vancouver
Mondal J, Chakraborty K, Bunggulawa EJ, An JM, Revuri V, Nurunnabi M, et al. Recent advancements of hydrogels in immunotherapy: Breast cancer treatment. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.06.003
BibTeX
@article{Mondal2024,
author = {Mondal, Jagannath and Chakraborty, Kushal and Bunggulawa, Edwin J and An, Jeong Man and Revuri, Vishnu and Nurunnabi, Md and Lee, Yong-Kyu},
title = {Recent advancements of hydrogels in immunotherapy: Breast cancer treatment},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.06.003}
}
EUVIMED